Abstract
Ciprofloxacin is a new fluoroquinolone derivative with a broad antibacterial spectrum. It is considerably more active than nalidixic acid against Enterobacteriaceae and is also active against organisms resistant to a wide range of antimicrobial agents of other groups such as beta-lactam antibiotics and aminoglycosides (1–3). Ciprofloxacin is well absorbed when administered orally. After a 500 mg single dose the peak level reaches about 2.5 mg/1 1 1/2 h after administration. Between 30% and 40% of the dose is recovered in urine during the 24 h following drug administration (3–6).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Van Caekenberthe, D. L., Stefaan, R., Pattyn, S. R.: In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substitutued quinoline derivatives. Antimicrobial Agents and Chemotherapy 1984, 25: 518–521.
Wise, R., Andrews, J. M., Edwards, L. J.: In vitro activity of Bay 0 9867, a new quinoline derivative, compared with that of other antimicrobial agents. Antimicrobial Agents and Chemotherapy 1983, 23: 559–564.
King, A., Shannon, K., Phillips, I.: The in vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin. Journal of Antimicrobial Chemotherapy 1985, 15: 551–558.
Gonzalez, M. A., Uribe, F., Duran, Moisen, S., Pichardo Fuster, A., Selen, A., Welling, P. G., Painter, B.: Multiple dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrobial Agents and Chemotherapy 1984, 26: 741–744.
Höffken, G., Lode, H., Prinzing, C., Borner, K., Koeppe, P.: Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrobial Agents and Chemotherapy 1985, 27: 375–379.
Crump, B., Wise, R., Dent, J.: Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrobial Agents and Chemotherapy 1983, 23: 784–786.
Guibert, J., Acar, J. F., Justin, C., Kitzis, M. D.: Evaluation clinique du céfotaxime à différents dosages thérapeutiques dans les infections urinaires. Nouvelle Presse Médicale 1981, 10: 625–627.
Guibert, J., Coppens, H., Yvelin, C.: Evaluation clinique du céfotiam dans les infections urinaires de l’adulte. Pathologie et Biologie 1982, 30: 353–356.
Guibert, J., Acar, J. F., Miegi, M.: Evaluation clinique de l’azthréonam dans les infections urinaires sévères. Pathologie et Biologie 1984, 32: 446–449.
Guibert, J., Acar, J. F., Destrée, D., Bryskier, A.: Evaluation clinique de la cefmenoxime dans les infections urinaires et prostatiques. Pathologie et Biologie 1985, 33: 330–334.
Author information
Authors and Affiliations
Editor information
Rights and permissions
Copyright information
© 1986 Springer Fachmedien Wiesbaden
About this chapter
Cite this chapter
Guibert, J., Destrée, D., Konopka, C., Acar, J. (1986). Ciprofloxacin in the Treatment of Urinary Tract Infection due to Enterobacteria. In: Neu, H.C., Reeves, D.S. (eds) Ciprofloxacin. Current Topics in Infectious Diseases and Clinical Microbiology, vol 1. Vieweg+Teubner Verlag, Wiesbaden. https://doi.org/10.1007/978-3-663-01930-5_34
Download citation
DOI: https://doi.org/10.1007/978-3-663-01930-5_34
Publisher Name: Vieweg+Teubner Verlag, Wiesbaden
Print ISBN: 978-3-663-01931-2
Online ISBN: 978-3-663-01930-5
eBook Packages: Springer Book Archive